/*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} Problem 53 The most common dose-limiting to... [FREE SOLUTION] | 91Ó°ÊÓ

91Ó°ÊÓ

The most common dose-limiting toxicity of chemotherapy is: 1\. nausea and vomiting. 2\. bloody stools. 3\. myelosuppression. 4\. inability to ingest food orally due to stomatitis and mucositis.

Short Answer

Expert verified
Myelosuppression is the most common dose-limiting toxicity of chemotherapy.

Step by step solution

01

Understand the Question

We need to identify which of the given options is the most common dose-limiting toxicity associated with chemotherapy treatments.
02

Evaluate Each Option

Consider the options provided: 1) nausea and vomiting, 2) bloody stools, 3) myelosuppression, and 4) inability to ingest food due to stomatitis and mucositis. Assess which of these is typically dose-limiting in chemotherapy.
03

Identify the Key Term: Dose-Limiting Toxicity

Dose-limiting toxicity is a side effect of a drug that prevents an increase in dose or level of that drug. It's important to note that while nausea and vomiting, and other adverse effects are common, myelosuppression is specifically known to limit chemotherapy dosing because it affects bone marrow.
04

Recognize Impact of Myelosuppression

Myelosuppression, the suppression of bone marrow activity, leads to reduced production of blood cells, increasing risk of infection, anemia, and bleeding, thus limiting the chemotherapy dose. This is typically the key limiting factor in adjusting chemotherapy dosage.
05

Select the Correct Answer

Based on the analysis, the most common dose-limiting toxicity of chemotherapy is myelosuppression.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Dose-Limiting Toxicity
When we talk about dose-limiting toxicity (DLT) in the context of chemotherapy, we are discussing the particular side effects that prevent the administration of higher doses of cancer-fighting medications. This term helps define the maximum tolerated dose (MTD) in patient treatments. The MTD is the highest dose of a drug that does not cause unacceptable side effects, allowing the patient to receive the most effective dose that minimizes damage to healthy cells. Understanding dose-limiting toxicity is crucial in cancer treatment as it directly influences how much of a drug a patient can safely receive. In many chemotherapy treatments, identifying dose-limiting toxicity is critical for balancing the therapeutic benefits and potential side effects. For instance, while nausea or vomiting can be severe, they are typically manageable and not dose-limiting. Myelosuppression is often the primary DLT in chemotherapy as it cannot be easily mitigated without altering the drug dose.
Myelosuppression
Myelosuppression refers to the decrease in production of blood cells in the bone marrow, a vital spongy tissue in our bones. This condition severely affects the production of white blood cells, red blood cells, and platelets. These components are essential for:
  • Fighting off infections (through white blood cells)
  • Transporting oxygen (via red blood cells)
  • Helping with blood clotting (via platelets)
Due to its critical functions, myelosuppression is a major concern in chemotherapy because it can lead to anemia (low red blood cells), increased risk of infections (low white blood cells), and bleeding or bruising (low platelets). As a dose-limiting toxicity, myelosuppression often necessitates adjustments in the chemotherapy dosing or may require supportive treatments like growth factors or blood transfusions to alleviate its effects. Balancing effective cancer treatment while minimizing myelosuppression is a delicate but essential task for healthcare providers.
Chemotherapy Side Effects
The side effects of chemotherapy can vary widely, largely depending on the drug used, dosage, and individual patient factors. Common side effects from chemotherapy include:
  • Nausea and vomiting
  • Mouth sores or mucositis
  • Fatigue
  • Hair loss
  • Constipation or diarrhea
  • Bleeding or bruising
These side effects arise because chemotherapy targets rapidly dividing cells, both cancerous and healthy, leading to a range of body system impacts. While many side effects are manageable and temporary, some like myelosuppression lead to critical concerns about dosage administration. Management of these effects often involves supportive medication, hydration, nutritional support, and careful monitoring. Educating patients about potential side effects helps them prepare and manage these issues effectively, ultimately aiming to complete the prescribed treatment regimen with the least discomfort and highest efficacy.

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

Drug interactions are more likely to occur when: 1\. the patient is elderly. 2\. the drugs are taken close together. 3\. the affected drug has a low therapeutic index. 4\. the patient is sedentary

A patient is receiving total parenteral nutrition (TPN). Today the physician orders an electrolyte panel. What would this laboratory test be used for in a patient on TPN? 1\. It wouldn’t. A more appropriate test would be liver function studies. 2\. It gives the physician a picture of the patient’s renal status. 3\. It provides information on the patient’s ability to manage the glucose load in his TPN. 4\. The physician can adjust the TPN solution electrolytes to meet the patient’s needs.

Local anesthetics block the conduction of pain impulses to the spinal cord. Their duration of action: 1\. is always longer than general anesthesia. 2\. is determined by the rate of diffusion and absorption at the site of administration. 3\. is usually short (10 minutes). 4\. varies, depending on the patient’s weight.

. A post-operative patient is receiving morphine sulfate via the intravenous route. Analgesia is effective. The physician changes the medication to the oral route at the same dosage. Subsequently, the patient states that he is getting very little pain relief. The nurse realizes that: 1\. the patient is becoming dependent on the drug. 2\. first pass effect is eliminating much of the oral dose. 3\. the patient is exhibiting drug-seeking behavior. 4\. tolerance to the medication has developed.

. In the adult population, total parenteral nutrition (TPN) may be administered for a certain number of hours per day. However, in the neonatal population, typically the solution is ordered to run continuously 24 hours per day. What is the rationale for infusing TPN continuously to neonates? 1\. It doesn’t interfer with nursing care. 2\. Babies don’t need nutrition in boluses to mimick meals. 3\. All neonates get all IV fluids on a continuous basis. 4\. It provides a constant energy and fluid source.

See all solutions

Recommended explanations on Biology Textbooks

View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.